NEWS AND INSIGHTS
Take Surge Pricing to the Limit. Then Go Further.News
The New York Times’ John Schwartz asks Eric Dezenhall about why Martin Shkreli the Turing Pharmaceutical executive who raised its drug Daraprim price to $750 a pill from $13.50 was vilified so quickly. Read the article for Eric’s simple answer.
From The New York Times
Eric Dezenhall, reputation management, Shkreli, surge pricing